Venus Remedies secures marketing approval from Israel, Colombia for two oncology drugs
The company has received marketing authorisation for docetaxel from Israel and cytarabine from Colombia
This significant milestone underscores Venus Remedies’ commitment to making a substantial impact in the oncology landscape in Israel and South America
Building on its international presence in the oncology space, Venus Remedies, a global leader in pharmaceutical innovation, has secured marketing authorisation for docetaxel from Israel and cytarabine from Colombia.
While docetaxel, an antineoplastic agent, is beneficial in the treatment of breast, prostate, head, neck and non-small cell lung cancer, cytarabine is useful in acute non-lymphocytic leukaemia, acute lymphocytic leukaemia and chronic myelocytic leukaemia.
Israel’s pharmaceutical market, valued at about $5 billion, is projected to grow at a five-year compound annual growth rate (CAGR) of 4.2% up to 2026. Israel has a dynamic pharmaceutical expanse known for its innovation and commitment to healthcare excellence. The marketing authorisation for cytarabine from Colombia, on the other hand, marks a significant expansion of Venus Remedies in the Latin American market. Colombia, the third-largest pharmaceutical market in South America projected to grow at a five-year CAGR of 3.1% up to 2026, has emerged as a vital player in the pharmaceutical industry, exhibiting robust growth and fostering innovation. The Colombian market dominated by oncology drugs has witnessed steady expansion.
Saransh Chaudhary, CEO, Venus Medicine Research Centre (VMRC), said these dual milestones reflect VMRC’s unwavering dedication to research and development. “Our team’s relentless pursuit of excellence in pharmaceutical innovation is evident in the approvals for docetaxel and cytarabine. We are excited about the prospect of bringing these advanced therapies to patients in Israel and Colombia, and we remain committed to exploring new frontiers in healthcare that align with our vision of a healthier world,” he said.
Hailing the achievement, Aditi K Chaudhary, President, International Business, Venus Remedies, said, “These marketing approvals mark a significant stride in our global mission to enhance healthcare accessibility. One of the largest exporters of docetaxel, Venus Remedies is proud to include Israel in the list of countries it supplies docetaxel to, including Malaysia, Namibia, Myanmar, Panama, Indonesia, Iraq, Tanzania, Germany, and Zimbabwe. Likewise, the market reach of Venus Remedies for cytarabine extends to Guinea-Bissau, Jordan, Namibia, Oman, Saudi Arabia, Tunisia and Venezuela, besides Colombia.”
About Venus Remedies
Panchkula-based Venus Remedies Ltd (NSE: VENUSREM, BSE: 526953) is among the 10 leading fixed-dosage injectable manufacturers in the world. Having a commercial presence in 70+ countries with a portfolio of 75 products spread over Europe, Australia, Africa, Asia-Pacific, Commonwealth States, the Middle East, Latin America and the Caribbean region, the company has nine globally benchmarked facilities in Panchkula, Baddi and Werne (Germany), apart from 11 overseas marketing offices. Its manufacturing units are certified for ISO 9001, ISO 14001, ISO 18001 and OHSAS. The company has also been approved by European-GMP, WHO-GMP and Latin American GMP (INVIMA), among others. Ranked 107th in Asia and among the world’s 500 largest pharmaceutical manufacturing companies, Venus Remedies has been granted more than 130 patents worldwide and having more than 125 registered trademarks and 25 copyrights for its innovative research products.
Reach out to us at PR Desk
Get rewarded for your reading habits on the Dais World app!